Analysis of Clinical Trials with Spencer Hey

What It Covers

Spencer Hey, cofounder of Prism, a metascience software company, describes how his philosophy-of-science background led him to build data visualization and LLM-powered tools that help biopharma organizations extract strategic knowledge from clinical trial data, reducing analysis turnaround from several weeks to days, with a goal of reaching hours.

Key Questions Answered

• •Metascience as a product category: Prism operates at the level above raw experimental data, analyzing sequences of hypotheses, trial outcomes, and research decisions across entire domains. In one published project with Genentech, the team used LLMs to extract central hypotheses from all neurodegenerative disease trials in PubMed, clustered them, and mapped neglected areas — a replicable framework for identifying white space in any therapeutic area.
• •Turnaround compression as a core metric: Prism measures its value by the time elapsed between a strategic question and a stakeholder-ready report. For one major pharma client's biomedical knowledge team, that window dropped from several weeks to roughly one week, then to days. The near-term product goal is a single natural-language prompt that triggers automated data retrieval, analysis, and formatted report generation within hours.
• •Interactive reports over static PowerPoints: Biopharma decisions frequently rest on static slide charts where underlying assumptions cannot be tested. Prism builds web-based, interactive visualizations using the Vega library, allowing decision-makers to adjust parameters and surface thousands of embedded sub-questions from a single report — shifting the baseline expectation from a fixed narrative to an explorable data artifact.
• •Three-pillar product architecture: Prism's platform rests on data visualization (Vega-based custom charts), data curation (ontology-explicit, provenance-tracked datasets), and generative insight (LLM agents that select chart types, format data, and execute multi-step research workflows). The third pillar is the current development focus, with the goal of configuring autonomous agent pipelines that execute full research plans from a single high-level instruction.
• •Epistemic humility as a sales positioning tool: Prism targets strategists inside pharma who already possess data but lack the infrastructure to communicate it persuasively to decision-makers. The product is not positioned as a replacement for domain expertise but as a tool that grounds existing beliefs in traceable evidence — shifting internal conversations from opinion-based table-pounding to data-backed, auditable arguments that stakeholders can interrogate directly.
• •Startup survival framed as continuous learning: Hey attributes Prism's resilience to a principle from the BC SSC accelerator: startups fail when founders stop learning, not when they run out of money. Practically, this means weekly iteration, treating the product team as a high-performance racing unit requiring alignment and marginal gains, and using Prism's own tools internally as a live test of whether the product meets the standard it promises clients.